ClearPoint Neuro, Inc.
ClearPoint Neuro, Inc. (CLPT) Financial Performance & Income Statement Overview
Analyze ClearPoint Neuro, Inc. (CLPT) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
ClearPoint Neuro, Inc. (CLPT) Income Statement & Financial Overview
View the income breakdown for ClearPoint Neuro, Inc. CLPT across both annual and quarterly reports.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $7.77M | $8.12M | $7.86M | $7.64M |
| Cost of Revenue | $3.009M | $3.27M | $2.87M | $3.11M |
| Gross Profit | $4.76M | $4.85M | $4.99M | $4.53M |
| Gross Profit Ratio | $0.61 | $0.60 | $0.63 | $0.59 |
| R&D Expenses | $3.33M | $3.31M | $3.12M | $2.63M |
| SG&A Expenses | $7.03M | $6.70M | $6.61M | $6.13M |
| Operating Expenses | $10.37M | $10.02M | $9.73M | $8.76M |
| Total Costs & Expenses | $13.38M | $13.29M | $12.60M | $11.87M |
| Interest Income | $226000.00 | $209000.00 | $326000.00 | $111000.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $471000.00 | $0.00 | $463000.00 | $474000.00 |
| EBITDA | -$5.13M | -$5.17M | -$4.28M | -$3.67M |
| EBITDA Ratio | -$0.66 | -$0.64 | -$0.54 | -$0.48 |
| Operating Income | -$5.60M | -$5.17M | -$4.74M | -$4.23M |
| Operating Income Ratio | -$0.72 | -$0.64 | -$0.60 | -$0.55 |
| Other Income/Expenses (Net) | $218000.00 | $198000.00 | $331000.00 | $85000.00 |
| Income Before Tax | -$5.39M | -$4.97M | -$4.41M | -$4.15M |
| Income Before Tax Ratio | -$0.69 | -$0.61 | -$0.56 | -$0.54 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $430724.00 |
| Net Income | -$5.39M | -$4.97M | -$4.41M | -$4.15M |
| Net Income Ratio | -$0.69 | -$0.61 | -$0.56 | -$0.54 |
| EPS | -$0.20 | -$0.18 | -$0.16 | -$0.16 |
| Diluted EPS | -$0.20 | -$0.18 | -$0.16 | -$0.16 |
| Weighted Avg Shares Outstanding | $27.62M | $27.59M | $27.47M | $25.45M |
| Weighted Avg Shares Outstanding (Diluted) | $27.62M | $27.59M | $27.47M | $25.45M |
Over the last four quarters, ClearPoint Neuro, Inc. achieved steady financial progress, growing revenue from $7.64M in Q1 2024 to $7.77M in Q4 2024. Gross profit stayed firm with margins at 61% in Q4 2024 versus 59% in Q1 2024. Operating income totaled -$5.60M in Q4 2024, maintaining a -72% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$5.13M. Net income dropped to -$5.39M, with EPS at -$0.20. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan